Comparison
Creatine Monohydrate vs Tirzepatide
Side-by-side of Creatine Monohydrate and Tirzepatide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Creatine Monohydrate
Creatine monohydrate supplement guide: 3-5 g/day raises phosphocreatine stores, lifts anaerobic output 5-15%, supports lean mass and cognition under sleep loss.
Tirzepatide
Tirzepatide for weight loss: dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound. SURMOUNT-1 showed 22.5% mean body-weight loss at 15 mg over 72 weeks.
Effects at a glance
Creatine Monohydrate
- •Increases anaerobic strength and power output by ~5 to 15% across multiple training studies
- •Adds ~1 to 2 kg of lean body mass over 4 to 12 weeks, partly intracellular water and partly true tissue gain
- •Improves 1-rep max on bench and squat by ~5 to 10% versus placebo in resistance-trained adults
- •Cognitive benefit appears mainly under sleep deprivation or high mental load, less so in well-rested individuals
- •Saturation reached in ~28 days at 3 to 5 g/day, or ~5 to 7 days with a 20 g/day loading phase
- •No evidence of renal harm in healthy adults across long-term studies; caution in pre-existing severe renal disease
Tirzepatide
- •Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
- •SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
- •Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
- •Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
- •GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
- •Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this
Side-by-side
| Attribute | Creatine Monohydrate | Tirzepatide |
|---|---|---|
| Category | supplement | pharmaceutical |
| Also known as | creatine | Mounjaro, Zepbound, LY3298176 |
| Half-life (hr) ↗ | 3 | 120 |
| Typical dose (mg) ↗ | 5000 | 10 |
| Dosing frequency | daily | weekly |
| Routes | oral | subcutaneous |
| Onset (hr) | 168 | 24 |
| Peak (hr) | - | 72 |
| Molecular weight | 149.15 | 4813.45 |
| Molecular formula | C4H9N3O2 | C225H348N48O68 |
| Mechanism | Donates a phosphate group to ADP via creatine kinase, regenerating ATP during high-intensity, short-duration efforts. | Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits. |
| Legal status | Dietary supplement (most jurisdictions) | Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound) |
| WADA status | allowed | allowed |
| DEA / Rx | OTC supplement | Rx only (not a controlled substance) |
| Pregnancy | Insufficient data | Not recommended; discontinue 2 months before planned pregnancy |
| CAS | 57-00-1 | 2023788-19-2 |
| PubChem CID | 586 | 156588324 |
| Wikidata | Q408389 | Q105099794 |
Safety profile
Creatine Monohydrate
Common side effects
- water retention
- mild GI upset at loading doses
- weight gain (2 to 4 lb from intracellular water)
Contraindications
- severe renal impairment
Interactions
- caffeine (high-dose acute): mixed data on ergogenic interference; chronic use appears compatible(minor)
- nephrotoxic drugs (NSAIDs, cyclosporine): theoretical additive renal strain in at-risk patients(moderate)
Tirzepatide
Common side effects
- nausea
- diarrhea
- vomiting
- constipation
- decreased appetite
- injection-site reactions
- fatigue
- abdominal pain
Contraindications
- personal or family history of medullary thyroid carcinoma
- multiple endocrine neoplasia type 2
- pregnancy
- history of pancreatitis (use caution)
- severe gastroparesis
Interactions
- insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
- sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
- oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
- oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
- warfarin: monitor INR due to altered absorption(moderate)
Which Should You Take?
Creatine Monohydrate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Tirzepatide is the right call when one of the conditionals below applies.
- → If your priority is strength or hypertrophy, pick Creatine Monohydrate.
- → If your priority is focus or working memory, pick Creatine Monohydrate.
- → If your priority is metabolic health and glucose control, pick Tirzepatide.
- → If your priority is fat loss, pick Tirzepatide.
Edge case: If you want to avoid prescription-only, Creatine Monohydrate is the more accessible choice.
Default choice: Creatine Monohydrate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Tirzepatide only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Creatine Monohydrate and Tirzepatide?
Creatine Monohydrate and Tirzepatide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Creatine Monohydrate or Tirzepatide?
Creatine Monohydrate half-life is 3 hours; Tirzepatide half-life is 120 hours.
Can you stack Creatine Monohydrate with Tirzepatide?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper